20825-87-0

Basic information

• Product Name: Ethyl2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate
• Synonyms: Ethyl2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate;1,4-Benzodioxin-6-carboxylic acid, 2,3-dihydro-, ethyl ester;2,3-Dihydrobenzo[1,4]dioxine-6-carboxylic acid ethyl ester
• CAS NO: 20825-87-0
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 207.20264
• Mol File: 20825-87-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 307.086°C at 760 mmHg
• Flash Point: 134.234°C
• Appearance: /
• Density: 1.205g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate(20825-87-0)
• EPA Substance Registry System: Ethyl2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate(20825-87-0)

Safety Data

• Hazardous Substances Data: 20825-87-0(Hazardous Substances Data)

Usage

General Description

Ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate is a chemical compound with the molecular formula C11H12O4. It is a derivative of benzo[b][1,4]dioxine, which is a heterocyclic compound containing two benzene rings fused to a 1,4-dioxin ring system. Ethyl2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate is commonly used in organic synthesis and pharmaceutical research. It is known for its potential pharmacological properties, including anti-inflammatory and analgesic effects. Ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate may also have applications in the development of new drugs for various medical conditions. However, further research is needed to fully understand its potential uses and effects.

InChI:InChI=1/C11H12O4/c1-2-13-11(12)8-3-4-9-10(7-8)15-6-5-14-9/h3-4,7H,2,5-6H2,1H3

Upstream product

• 64-17-5 ethanol 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 3943-89-3 Ethyl protocatechuate 
• 106-93-4 ethylene dibromide 

Downstream Products

• 26309-99-9 6-(chloromethyl)-2,3-dihydrobenzo[b][1,4]dioxine 
• 928710-56-9 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1,3,4-oxadiazole-2-thiol 
• 1403750-39-9 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(2-fluorophenyl)-3-(4-methoxybenzyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone 
• 1403750-38-8 (3-(4-bromophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone 
• 1403750-37-7 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(2-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone 
• 1403750-36-6 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(3-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone 
• 1403750-35-5 (3-(4-bromophenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone 
• 1403750-34-4 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone 
• 1403750-33-3 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone 
• 1403750-32-2 (3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone 
• 1403750-31-1 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(4-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone 
• 1403750-30-0 (3,5-bis(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone 
• 1403750-29-7 (3-(4-bromophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanone 
• 1403750-26-4 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone 

Relevant articles and documents

Synthesis and antibacterial activity of cinnamaldehyde acylhydrazone with a 1,4-benzodioxan fragment as a novel class of potent ss-Ketoacyl-acyl carrier protein synthase III (FabH) inhibitor

Fatty acid biosynthesis is essential for bacterial survival. ss-Ketoacyl-acyl carrier protein (ACP) synthase III (FabH), is a particularly attractive antibacterial target, since it is central to the initiation of fatty acid biosynthesis. Three series of 2

Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 ± 0.2, 30.0 ± 1.2, 18.3 ± 1.4 μM, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 μM, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 μg/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study.

Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4] dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase

Two series of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives C1-C15 and D1-D15 have been synthesized and evaluated for their B-Raf inhibitory and anti-proliferation activities. Compound C14 ((3-(4-bromophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methanone) showed the most potent biological activity against B-RafV600E (IC50 = 0.11 μM) and WM266.4 human melanoma cell line (GI50 = 0.58 μM), being comparable with the positive control Erlotinib and more potent than our previous best compound, while D10 ((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)(5-(3- fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone) performed the best in the D series (IC50 = 1.70 μM; GI50 = 1.45 μM). The docking simulation was performed to analyze the probable binding models and poses and the QSAR model was built for reasonable design of B-Raf inhibitors in future. The introduction of 2,3-dihydrobenzo[b][1,4]dioxin structure reinforced the combination of our compounds and the receptor, resulting in progress of bioactivity.